Drug Trial Radar · NCT01772472
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
Last checked: Nov 20, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,486
Actual
Start
Apr 3, 2013
Primary completion
Jul 25, 2018
Study completion May 23, 2024
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- NSABP Foundation Inc; GBG Forschungs GmbH
- First posted
- Jan 21, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.
Conditions
- Breast Cancer
Interventions
trastuzumabDrug
6 mg/kg intravenously every 3 weeks, 14 cycles
trastuzumab emtansineDrug
3.6 mg/kg intravenously every 3 weeks, 14 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive Disease-free Survival (IDFS) Rate at 3 YearsTime frame: At Year 3
Locations
268 sites in 28 countries. Site status is shown where the registry gives one.
Providence Alaska Medical Center
Anchorage, Alaska
Todd Cancer Institute at Long Beach Memorial Medical Center
Long Beach, California
Chao Family Comprehensive Cancer Center
Orange, California
Stanford University Medical Center
Palo Alto, California
Kaiser Permanente - San Diego
San Diego, California
Breastlink Medical Group Inc
Santa Ana, California
Kaiser Permanente - Vallejo
Vallejo, California
Kaiser Permanente - Franklin
Denver, Colorado
Colorado Cancer Research Program/Admin
Denver, Colorado
Yale Cancer Center
New Haven, Connecticut
Washington Cancer Institute
Washington D.C., District of Columbia
University of Florida
Gainesville, Florida
Mount Sinai Medical Center
Miami Beach, Florida
UF Health Orlando
Orlando, Florida
Moffitt Cancer Center
Tampa, Florida
Rush University Medical Center
Chicago, Illinois
Edward Cancer Center Naperville
Naperville, Illinois
Edward Cancer Center Plainfield
Plainfield, Illinois
University of Iowa
Iowa City, Iowa
University of Kentucky Medical Center
Lexington, Kentucky
Norton Healthcare Inc.
Louisville, Kentucky
Cancer Care of Maine
Brewer, Maine
New England Cancer Specialists
Scarborough, Maine
Mercy Medical Center
Baltimore, Maryland
Greater Baltimore Medical Center
Baltimore, Maryland
Med Star Franklin Square Medical Center/Weinburg Cancer Institute
Baltimore, Maryland
Karmanos Cancer Institute
Detroit, Michigan
Henry Ford Health System
Detroit, Michigan
Spectrum Health Hospitals
Grand Rapids, Michigan
Breslin Cancer Center
Lansing, Michigan
William Beaumont Hospital
Royal Oak, Michigan
US oncology research at Minnesota Oncology
Saint Louis Park, Minnesota
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Sparta Cancer Center
Sparta, New Jersey
Columbia University Medical Center
New York, New York
Troy Cancer Treatment Program
Troy, New York
Carolinas Medical Center
Charlotte, North Carolina
Sanford Roger Maris Cancer Center
Fargo, North Dakota
Aultman Hospital
Canton, Ohio
Fairview Hospital
Cleveland, Ohio
Showing 40 of 268 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.